CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and functionDuohui Jing, Martin Bornhäuser, Rainer Ordemann et al.|Bone Marrow Transplantation|2010Cited by 56